专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2007217407A Pharmaceutical composition 审中-公开
标题翻译：药物组合物
公开(公告)号：JP2007217407A
公开(公告)日：2007-08-30
申请号：JP2007008617
申请日：2007-01-18
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： TAKAMURO IWAO , KAWANAMI SABURO , TSUBOI YASUNORI , MOCHIDA HIDEKI , NOSHIRO KOJI
IPC分类号： A61K31/519 , A61P1/00 , A61P1/04 , A61P1/10 , A61P13/10 , A61P21/04 , A61P25/00 , A61P25/28 , A61P43/00 , C07D487/04
摘要： PROBLEM TO BE SOLVED: To provide a medicine containing pyrazolopyrimidine compound having SK channel-blocking activities as an active ingredient. SOLUTION: The pharmaceutical composition contains a compound represented by general formula [I] [wherein, A is a group represented by formula (a) or (b); R 11 and R 12 are each hydrogen, an alkyl or the like, or form a nitrogen-containing heterocycle by bonding to each other; R 13 and R 14 are each hydrogen, an alkyl, a hydroxyalkyl or the like; Q is an alkylene; R 2 is a group represented by formula [II]; R 30 is a halogen; R 31 is a halogen-substituted alkyl or the like; R 32 , R 33 , R 34 and R 35 are each an alkyl, an alkoxy or the like; R 36 , R 37 and R 38 are each an alkyl, an alkoxy or the like; n is 0 or 1 (with the proviso that when A is a group represented by formula (a); R 32 , R 33 and R 34 are not an alkyl or an alkoxy)], or a pharmacologically acceptable salt thereof as an active ingredient. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供含有具有SK通道阻断活性的吡唑并嘧啶化合物作为活性成分的药物。解决方案：药物组合物含有由通式[I]表示的化合物[其中，A是由式（a）或（b）表示的基团。 R 11和R 12各自为氢，烷基等，或通过彼此键合形成含氮杂环; R 13和R 14各自为氢，烷基，羟基烷基等; Q是亚烷基; R 2是由式[II]表示的基团。 30 是卤素; R 30是卤素取代的烷基等; R SP 30，R 32，SP 30，R 32，SP 30，R 32， R SP 30，R SP 37，和R 30 SP 30各自为烷基，烷氧基等; n为0或1（前提条件是当A为式（a）表示的基团时，R 32为SP，R 34为SP >不是烷基或烷氧基）]或其药理学上可接受的盐作为活性成分。版权所有（C）2007，JPO＆INPIT

2. 发明专利

JP2007161674A Piperidine compound and its production method 审中-公开
标题翻译：哌啶化合物及其生产方法
公开(公告)号：JP2007161674A
公开(公告)日：2007-06-28
申请号：JP2005362537
申请日：2005-12-16
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： SAKURAI OSAMU , IKEDA YOSUKE , MIYAKE TSUTOMU
IPC分类号： C07D211/98 , A61K31/451 , A61K31/453 , A61K31/4545 , A61P1/00 , A61P1/04 , A61P1/08 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P11/10 , A61P11/14 , A61P13/10 , A61P17/00 , A61P17/04 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/04 , A61P37/00 , A61P37/08 , A61P43/00 , C07D211/62 , C07D213/79 , C07D401/12 , C07D405/12
摘要： PROBLEM TO BE SOLVED: To provide a piperidine compound having an excellent tachykinin receptor-antagonizing activity. SOLUTION: This piperidine compound represented by the general formula [I] [the ring A is a benzene ring which may have one or more substituents; the ring B is a benzene ring which may have one or more substituents; R is H or an alkyl group which may have one or more substituents; X is a group represented by -CO-, -SO- or -SO 2 -; (m) is an integer of 1 or 0; R 1 is an alkyl which may have one or more substituents, a cycloalkyl which may have one or more substituents, or the like; Z is O or -N(R 3 )-; R 3 is H or an alkyl which may have one or more substituents; R 4a or R 4b are identically or differently H or an alkyl which may have one or more substituents, or ; R 4a and R 4b may be bound to each other at their ends to form an alkylene] or its pharmacologically acceptable salt. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：提供具有优异的速激肽受体拮抗活性的哌啶化合物。解决方案：由通式[I]表示的哌啶化合物[环A是可具有一个或多个取代基的苯环; 环B是可以具有一个或多个取代基的苯环; R是H或可以具有一个或多个取代基的烷基; X是由-CO - ， - SO-或-SO 2 -S-表示的基团。（m）为1或0的整数; R SP 1是可以具有一个或多个取代基的烷基，可以具有一个或多个取代基的环烷基等; Z是O或-N（R 3 SP 3） - ; R 3是H或可以具有一个或多个取代基的烷基; 或者R“S 4”4b相同或不同的是H或可以具有一个或多个取代基的烷基，或者 R 4和R 4可以在其末端彼此结合形成亚烷基]或其药理学上可接受的盐。版权所有（C）2007，JPO＆INPIT

3. 发明专利

JP2007091732A Thiomorpholine compound and method for producing the same 审中-公开
标题翻译：噻咯啉化合物及其生产方法
公开(公告)号：JP2007091732A
公开(公告)日：2007-04-12
申请号：JP2006234808
申请日：2006-08-31
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： TAKAHASHI MASAMI , YAMANAKA TAKESHI , MIYAKE TSUTOMU
IPC分类号： C07D211/58 , A61K31/541 , A61P1/00 , A61P1/04 , A61P1/08 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P11/10 , A61P11/14 , A61P13/10 , A61P17/00 , A61P17/04 , A61P17/06 , A61P19/02 , A61P19/10 , A61P25/00 , A61P25/02 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/04 , A61P37/00 , A61P37/08 , A61P43/00 , C07D211/44
摘要： PROBLEM TO BE SOLVED: To obtain a thiomorpholine compound having excellent tachykinine recipient antagonist activity. SOLUTION: The thiomorpholine compound expressed by general formula [I] (wherein the ring A expresses a benzene ring which may have a substituent; the ring B expresses a benzene ring which may have a substituent; R 1 expresses H, an hydroxyl which may have a substituent, an amino which may have a substituent, an alkyl which may have a substituent, a carbonyl having a substituent, or a halogen atom; R 2 expresses H or an alkyl which may have a substituent; R 3a and R 3b are the same or different and express each H, an alkyl which may have a substituent, or a group forming an alkylene group by bonding at terminals; n expresses 1 or 2 integer) or a pharmaceutically permissible salt of the same are claimed. COPYRIGHT: (C)2007,JPO&INPIT
摘要翻译：待解决的问题：获得具有优异的速激肽受体拮抗剂活性的硫代吗啉化合物。解决方案：由通式[I]表示的硫代吗啉化合物（其中环A表示可具有取代基的苯环;环B表示可具有取代基的苯环; R SP>表示H，可以具有取代基的羟基，可以具有取代基的氨基，可以具有取代基的烷基，具有取代基的羰基或卤素原子; R SP＆gt; 2表示 H或可以具有取代基的烷基; R 3和R 3彼此相同或不同，表示每个H，可以具有取代基的烷基或基团通过在末端键合形成亚烷基; n表示1或2个整数）或其药学上允许的盐。版权所有（C）2007，JPO＆INPIT

4. 发明专利

JP2006187636A Method of stabilizing vitamin b1-containing aqueous formulation 审中-公开
标题翻译：维生素B1含水质配方的稳定方法
公开(公告)号：JP2006187636A
公开(公告)日：2006-07-20
申请号：JP2006024499
申请日：2006-02-01
申请人： Tanabe Seiyaku Co Ltd , Terumo Corp , テルモ株式会社 , 田辺製薬株式会社
发明人： OSHIMA HIDEHIKO , YAMASHITA KANAKO , MATSUDA SABURO , KURUMA CHIE
IPC分类号： A61J1/14 , A61J1/05 , A61J3/00 , A61K9/08 , A61K31/07 , A61K31/122 , A61K31/164 , A61K31/198 , A61K31/355 , A61K31/375 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K31/4188 , A61K31/4415 , A61K31/455 , A61K31/51 , A61K31/525 , A61K31/59 , A61K31/7004 , A61K31/714 , A61K33/00 , A61K33/14 , A61K33/24 , A61K33/30 , A61K47/02 , A61K47/30 , A61P3/02 , A61P3/08 , A61P3/12 , A61P3/14
摘要： PROBLEM TO BE SOLVED: To provide an improved method of stabilizing a vitamin B1-containing aqueous formulation by which the vitamin B1-containing formulation may be stably kept for a long time. SOLUTION: In this method, a vitamin B1-containing aqueous formulation is filled into a gas permeable primary vessel and is sealed together with an oxygen scavenger into a secondary vessel comprising a gas hardly-permeable film with an aluminum evaporation layer or aluminum foil layer. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供一种稳定含有维生素B1的水性制剂的改进方法，其中含有维生素B1的制剂可以长期稳定地保持。解决方案：在该方法中，将含维生素B1的水性制剂填充到透气性初级容器中，并与氧清除剂一起密封到具有铝蒸发层或铝的气体难渗透膜的二次容器中箔层。版权所有（C）2006，JPO＆NCIPI

5. 发明专利

JP2005335761A Alteration preventive packaging case and storage case 审中-公开
标题翻译：更换预防性包装盒和存储盒
公开(公告)号：JP2005335761A
公开(公告)日：2005-12-08
申请号：JP2004157656
申请日：2004-05-27
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： OGINO TETSUYA
IPC分类号： B65D5/54 , B65D5/42 , B65D5/60
摘要： PROBLEM TO BE SOLVED: To provide an alteration preventive packaging case for surely and easily sealing and for surely revealing alteration when it is altered with avoiding concealing of the alteration. SOLUTION: This packaging case has a bottomed quadrangle prism shaped case main body 1 with an open top 6 having a pair of front and back side panels 2a, 2b and a pair of right and left side panels 3a, 3b, and a cover body 5 with a hanging cover piece 4 to be inserted in the inner face side of the front side panel 2a is jointly connected to the back side panel 2b folded to open/close the opening 6. A supported panel 7 supported in the main body 1 and closely positioned along the panel 2a is additionally provided. The piece 4 and the panel 7 are provided with the first and the second bending flaps 8, 9 respectively on the inside top and the outside bottom being bent, and the piece 4 and the panel 7 are formed to catch each other when the tip end 8a of the flap 8 touches the bending part 9a of the flap 9. The part 9b of the flap 9 is formed with an easily breakable part which is broken when the tip end 8a of the flap 8 presses the same. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：要解决的问题：提供一种可靠且易于密封的防变化包装盒，并且在改变时肯定地显示改变，同时避免隐藏变更。解决方案：该包装盒具有底部的四边形棱镜形壳体主体1，其具有敞开的顶部6，其具有一对前侧面板2a和后侧面板2b，以及一对左右侧面板3a，3b和具有插入前侧面板2a的内表面侧的悬挂盖片4的盖体5共同连接到折叠以打开/关闭开口6的后侧面板2b。支撑在主体中的支撑面板7 另外提供了沿着面板2a紧密定位的图1。片4和面板7分别设置有第一和第二弯折片8,9分别在内侧顶部和外侧底部弯曲，并且片状物4和面板7形成为当前端翼片8的8a 8a接触翼片9的弯曲部分9a。翼片9的部分9b形成有易于断裂的部分，当翼片8的尖端8a按压时，该部分破裂。版权所有（C）2006，JPO＆NCIPI

6. 发明专利

JP2005255675A Pharmaceutical composition 审中-公开
标题翻译：药物组合物
公开(公告)号：JP2005255675A
公开(公告)日：2005-09-22
申请号：JP2005033237
申请日：2005-02-09
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： WITHERINGTON JASON , ELLIOT RICHARD LEONARD
IPC分类号： C07D213/64 , A61K31/4418 , A61P1/00 , A61P1/16 , A61P1/18 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/02 , A61P11/06 , A61P13/12 , A61P15/00 , A61P15/14 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P25/02 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/04 , A61P31/18 , A61P35/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition effectively suppressing or inhibiting α 4 -integrin-interposed cell adhesion and effective for preventing or treating chronic inflammatory diseases. SOLUTION: This pharmaceutical composition contains as active ingredient a compound of formula(I) having α 4 -integrin-interposed cell adhesion inhibitory activity or a pharmaceutically acceptable derivative thereof. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题：获得有效抑制或抑制α整合素介导的细胞粘附并有效预防或治疗慢性炎性疾病的药物组合物。
解决方案：该药物组合物含有作为活性成分的具有α 4整体素介导的细胞粘附抑制活性的式（I）化合物或其药学上可接受的衍生物。版权所有（C）2005，JPO＆NCIPI

7. 发明专利

JP2005120080A Medicinal composition 有权
标题翻译：药物组合物
公开(公告)号：JP2005120080A
公开(公告)日：2005-05-12
申请号：JP2004276276
申请日：2004-09-24
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： KAWAGUCHI TAKAYUKI , AKATSUKA HIDENORI , IIJIMA TORU , TSUBOI YASUNORI , MITSUI TAKASHI , MURAKAMI JUN
IPC分类号： C07D307/85 , A61K31/343 , A61K31/4025 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/4525 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , A61P3/10 , A61P7/00 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/08 , A61P9/10 , A61P11/00 , A61P13/12 , A61P25/00 , A61P29/00 , A61P37/06 , A61P43/00 , C07D405/12 , C07D405/14 , C07D413/14 , C07D417/14
摘要： PROBLEM TO BE SOLVED: To provide a medicinal composition containing a benzofuran derivative or its salt as an active component, and a FXa inhibitor. SOLUTION: This medicinal composition consists of a benzofuran derivative expressed by general formula [1] [wherein, X is a group expressed by formula: -N= or formula: -CH=; Y is amino group which may be substituted, a cycloalkyl group which may be substituted or a saturated heterocyclic group which may be substituted; A is a single bond, a carbon chain which may have a double bond in the chain or at the terminal of the chain, or O; R 1 is H, a halogen atom or the like; ring B expressed by formula [a] is a benzene ring which may be substituted; and R 3 is H or the like], or its pharmacologically acceptable salts and a pharmacologically acceptable carrier. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：待解决的问题：提供含有苯并呋喃衍生物或其盐作为活性成分的药物组合物和FXa抑制剂。解决方案：该药物组合物由通式[1]表示的苯并呋喃衍生物[其中，X为下式表示的基团：-N =或式：-CH =; Y可以被取代的氨基，可被取代的环烷基或可被取代的饱和杂环基; A是单键，可以在链中或链末端具有双键的碳链，或O; R 1是H，卤素原子等; 由式[a]表示的环B是可以被取代的苯环; 和R 3是H等等，或其药理学上可接受的盐和药理学上可接受的载体。版权所有（C）2005，JPO＆NCIPI

8. 发明专利

JP2005104838A Condensed furan compound 审中-公开
标题翻译：浓缩的呋喃化合物
公开(公告)号：JP2005104838A
公开(公告)日：2005-04-21
申请号：JP2003334598
申请日：2003-09-26
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： KAWAGUCHI TAKAYUKI , AKATSUKA HIDENORI , IIJIMA TORU , WATANABE TATSUYA , MURAKAMI JUN , MITSUI TAKASHI
IPC分类号： A61K31/4355 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P13/12 , A61P25/00 , A61P29/00 , A61P37/06 , A61P43/00 , C07D20060101 , C07D213/75 , C07D491/04 , C07D491/048
CPC分类号： C07D491/04 , C07D213/75
摘要： PROBLEM TO BE SOLVED: To obtain a condensed furan compound useful as an activated coagulant factor X inhibitor. SOLUTION: This compound is represented by formula (I) (wherein, ring X denotes a benzene or a pyridine; Y denotes an amino which may be substituted, a cycloalkyl which may be substituted, a saturated heterocyclic group which may be substituted or an unsaturated heterocyclic group which may be substituted; A denotes a single bond, a lower alkylene, a lower alkyenylidene, a lower alkenylene or an oxygen atom; R 1 s denote each hydrogen, a halogen, or the like; R 3 denotes hydrogen, or the like; and R 4 denotes hydrogen, or the like) or its salt. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：待解决的问题：获得可用作活化凝血因子X抑制剂的冷凝呋喃化合物。解决方案：该化合物由式（I）表示（其中，环X表示苯或吡啶; Y表示可被取代的氨基，可被取代的环烷基，可被取代的饱和杂环基或可以被取代的不饱和杂环基; A表示单键，低级亚烷基，低级亚烯基，低级亚烯基或氧原子; R表示各个氢，卤素或其中R 3表示氢等，R 4表示氢，或类似物）或其盐。版权所有（C）2005，JPO＆NCIPI

9. 发明专利

JP2005097126A Diltiazem pharmaceutical preparation for oral administration 审中-公开
标题翻译：用于口服管理的DILTIAZEM药物制剂
公开(公告)号：JP2005097126A
公开(公告)日：2005-04-14
申请号：JP2003329625
申请日：2003-09-22
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： SUGIMOTO MASAAKI , KINOSHITA HAJIME , TAMURA TAKASHI
IPC分类号： A61K9/32 , A61K9/48 , A61K31/554 , A61K47/02 , A61K47/12 , A61K47/22 , A61K47/32 , A61K47/34 , A61K47/38
摘要： PROBLEM TO BE SOLVED: To provide a diltiazem pharmaceutical preparation for oral administration with controlled elution. SOLUTION: This diltiazem pharmaceutical preparation for the oral administration is composed of (a) a core containing diltiazem hydrochloride, an organic acid and a water-soluble pharmacologically acceptable synthetic polymer, (b) a coating covering the core and containing a water-insoluble and water-swellable polymer and talc and (c) an outer layer containing the diltiazem hydrochloride, an organic acid and a water-soluble pharmacological acceptable synthetic polymer and covering the coating. COPYRIGHT: (C)2005,JPO&NCIPI

10. 发明专利

JP2005068145A Pharmaceutical composition 审中-公开
标题翻译：药物组合物
公开(公告)号：JP2005068145A
公开(公告)日：2005-03-17
申请号：JP2004230969
申请日：2004-08-06
申请人： Tanabe Seiyaku Co Ltd , 田辺製薬株式会社
发明人： YLLA SAAKAA , MORNINGSTAR MARSHALL , KADOSHIMA MASATOSHI , KAJI HIDEFUMI , KAWAGUCHI TAKAYUKI , KUME TOSHIYUKI
IPC分类号： C07D487/04 , A61K31/4188 , A61P1/00 , A61P1/04 , A61P3/10 , A61P7/02 , A61P9/08 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/10 , A61P17/00 , A61P17/02 , A61P19/02 , A61P19/10 , A61P25/00 , A61P27/02 , A61P29/00 , A61P35/00 , A61P37/02 , A61P37/08 , A61P43/00
摘要： PROBLEM TO BE SOLVED: To provide a pharmaceutical composition useful for treating or preventing an α
L β
2 integrin-mediated pathologic state and a substance P-related pathologic state.
SOLUTION: This pharmaceutical composition contains a compound expressed by formula (I) (R is H, hydroxyl or carbamoyl; and n is 1 or 2) or a pharmacologically acceptable salt thereof as an active ingredient.
COPYRIGHT: (C)2005,JPO&NCIPI

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式